First-Line Osimertinib for Patients With EGFR Advanced NSCLC First-Line Osimertinib for Patients With EGFR Advanced NSCLC
What have we learned about the safety and efficacy of osimertinib for the first-line treatment of patients with EGFR-mutated advanced NSCLC?Translational Lung Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Cancer | Cancer & Oncology | Health | Hematology | Lung Cancer | Non-Small Cell Lung Cancer